Chemical formula: C₃₉H₄₃N₃O₁₁S Molecular mass: 761.837 g/mol PubChem compound: 108150
Trabectedin is indicated for:
Population group: only adults (18 years old or older)
Trabectedin is indicated for the treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: women, only adults (18 years old or older)
Trabectedin in combination with pegylated liposomal doxorubicin (PLD) is indicated for the treatment of patients with relapsed platinum-sensitive ovarian cancer.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Trabectedin is contraindicated in the following cases:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
